Context Therapeutics (CNTX) Other Working Capital Changes (2022 - 2026)
Context Therapeutics (CNTX) posted Other Working Capital Changes of -$30698.0 for Q1 2026, down 9.11% sequentially from -$28136.0 in Q4 2025, and down 19.57% YoY from -$38166.6 in Q1 2025.
Context Therapeutics (CNTX) Other Working Capital Changes (2022 - 2026) Analysis & Trends
Context Therapeutics has reported Other Working Capital Changes for 5 years, with the latest figure at -$30698.0 in Q1 2026.
- Quarterly Other Working Capital Changes fell 19.57% year-over-year to -$30698.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$112340.0 (down 67.84% YoY) and the FY2025 annual result came in at -$107316.0, down 160.11% from the prior year.
- Other Working Capital Changes retreated to -$30698.0 in Q1 2026 per CNTX's latest filing, from -$28136.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $2.2 million in Q4 2024 and troughed at -$1.3 million in Q3 2025.
- A 5-year average of $97926.9 and a median of $107632.0 in 2024 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 65.11% in 2023, down 238.72% in 2023.
- Over 5 years, Other Working Capital Changes stood at -$23119.0 in 2022, then jumped by 65.54% to -$7967.0 in 2023, then sank by 213.54% to -$24980.0 in 2024, then fell by 12.63% to -$28136.0 in 2025, then dropped by 9.11% to -$30698.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$30698.0, -$28136.0, and -$27119.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - |
| 10 | Context Therapeutics | 50.91 Mn | 50.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37,432.00 |
| Jun 30, 2026 | -37,432.00 |
| Jun 30, 2026 | -37,432.00 |
| Mar 31, 2026 | -30,698.00 |
| Mar 31, 2026 | -30,698.00 |
| Mar 31, 2026 | -30,698.00 |
| Dec 31, 2025 | -28,136.00 |
| Dec 31, 2025 | -28,136.00 |
| Dec 31, 2025 | -28,136.00 |
| Sep 30, 2025 | -27,119.00 |
| Sep 30, 2025 | -27,119.00 |
| Sep 30, 2025 | -27,119.00 |
| Jun 30, 2025 | -26,387.00 |
| Jun 30, 2025 | -26,387.00 |
| Jun 30, 2025 | -26,387.00 |
| Mar 31, 2025 | -25,674.00 |
| Mar 31, 2025 | -25,674.00 |
| Mar 31, 2025 | -25,674.00 |
| Dec 31, 2024 | -24,980.00 |
| Dec 31, 2024 | -24,980.00 |